ACS chemical neuroscience molecule spotlight on Lorcaserin

Corey R Hopkins

doi:10.1021/cn100059u

ACS chemical neuroscience molecule spotlight on Lorcaserin

ACS Chem Neurosci. 2010 Nov 17;1(11):718-9. doi: 10.1021/cn100059u.

Author

Corey R Hopkins¹

Affiliation

¹ Department of Pharmacology and Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center, Vanderbilt University, Nashville, Tennessee 37232-6600, USA.

Abstract

Lorcaserin (APD-356) is the first in a new class of selective serotonin 5-hydroxytryptamine(2C) (5-HT(2C)) receptor agonists. On December 22, 2009, the compound's developer (Arena Pharmaceuticals) submitted an NDA to the FDA for approval for weight management.

Keywords: Lorcaserin; selective serotonin 5-HT2C receptor agonist; weight loss.

Publication types

Review

MeSH terms

Anti-Obesity Agents / chemistry
Anti-Obesity Agents / pharmacology*
Benzazepines / chemistry
Benzazepines / pharmacology*
Clinical Trials, Phase III as Topic
Humans
Obesity / drug therapy
Receptor, Serotonin, 5-HT2C / drug effects*
Serotonin 5-HT2 Receptor Agonists / chemistry
Serotonin 5-HT2 Receptor Agonists / pharmacology*
United States
United States Food and Drug Administration

Substances

Anti-Obesity Agents
Benzazepines
Receptor, Serotonin, 5-HT2C
Serotonin 5-HT2 Receptor Agonists
lorcaserin